Alexza Pharmaceuticals, Inc. focuses on the development and commercialization of proprietary products for the treatment of acute and intermittent conditions. The company develops products by utilizing its proprietary technology, Staccato system, which vaporizes unformulated drug compounds to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The company has four clinical stage product candidates that include: AZ-001 (Staccato prochlorperazine) to treat patients suffering from acute migraine headaches, AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder, AZ-003 (Staccato fentanyl) for the management of acute breakthrough pain, and AZ-004 and AZ-104 (Staccato loxapine) for the treatment of acute agitation in patients with schizophrenia and migraine. Alexza has a development agreement with Autoliv ASP, Inc. for the development of heat packages that can be incorporated into single dose drug delivery device. Alexza Pharmaceuticals, formerly known as FaxMed, Inc., was founded in December 2000. The company is based in Palo Alto, California and employs approximately 150 professionals.
(Read more at Wikinvest )